World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
World Lung 2024 – a way forward for CEACAM5?
Patients' expression of CEACAM5 might hold the key to activity after all.
An alpha turnaround for Relay
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
World Lung 2024 – ArriVent looks for lung cancer white space
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
World Lung 2024 – picking apart the Harmoni-2 win
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
World Lung 2024 – backing for ifinatamab’s pivotal move
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
The pieces of Vor’s puzzle start to come together
The depressed company could use Mylotarg as a stepping stone in AML.
